Author Archives: Isaura Santos

Amarantus Creates Alzheimer’s Disease Diagnostics Scientific Advisory Board

Amarantus BioScience Holdings, Inc., a biotechnology company committed to developing diagnostics in neurology and to advance therapeutic products in several areas such as neurology, ophthalmology, psychiatry and regenerative medicine, recently announced the formation of an Alzheimer’s disease Diagnostics Scientific Advisory Board (SAB). The company also designated three renowned experts in Alzheimer’s disease and neurological disorders as its first members: Paula…

AC Immune Signs With Janssen Pharmaceuticals for Alzheimer’s Disease Treatment Using Anti-Tau Vaccination

AC Immune SA recently announced it has signed an exclusive worldwide license agreement and collaboration contract with Janssen Pharmaceuticals, Inc. to develop and commercialize anti-Tau vaccines to treat Alzheimer’s disease. According to the contract, Janssen Research & Development, an affiliate of Janssen Pharmaceuticals, Inc., will advance the development of the vaccine ACI-35 which is…

Insulin Nasal Spray Improves Alzheimer’s Cognitive Impairment, Study Shows

A research team from the Wake Forest Baptist Medical Center developed a form of insulin intended to be delivered via nasal spray that can have positive results on mental capabilities, such as the working memory of adults suffering from Alzheimer’s disease and other mental and cognitive impairments. The study examined the nasal spray’s effects on 60 adults diagnosed with amnesic mild…

Alzheimer’s Disease Receives 2015 Federal Funding Boost

An important victory for Alzheimer’s disease patients advocates occurred last month when the U.S. Congress approved legislation that can significantly increase the federal budget allotted for research and development on newer and better approaches to prevent and treat this common form of dementia. Larisa Kofman, the public policy director for the Alzheimer’s Association’s Oregon…

SCarletRoAD Trial of Gantenerumab in Prodromal Alzheimer’s Discontinued

German biotechnology company, MorphoSys, was informed by its partner, Swiss global health-care company, Roche, about their decision to discontinue gantenerumab‘s Phase III SCarletRoAD trial for prodromal Alzheimer’s Disease patients. This decision is supported by a recommendation from the Independent Data Monitoring Committee, and by a pre-planned futility assessment. According to Roche, the trial was…

NDA for Alzheimer’s Combined Drug Namzaric Approved by FDA

Actavis and Adamas Pharmaceuticals Inc. announced that the US Food and Drug Administration has accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, for the treatment of moderate to severe Alzheimer’s Disease in patients stabilized on memantine hydrochloride…